Stuart Chaussee & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-300
| Closed | -$7.64K | – | 108 |
|
|
2025
Q3 | $7.64K | Hold |
300
| – | – | ﹤0.01% | 156 |
|
|
2025
Q2 | $7.27K | Hold |
300
| – | – | ﹤0.01% | 158 |
|
|
2025
Q1 | $7.6K | Hold |
300
| – | – | ﹤0.01% | 160 |
|
|
2024
Q4 | $7.96K | Hold |
300
| – | – | ﹤0.01% | 156 |
|
|
2024
Q3 | $8.68K | Hold |
300
| – | – | ﹤0.01% | 137 |
|
|
2024
Q2 | $8.39K | Hold |
300
| – | – | ﹤0.01% | 132 |
|
|
2024
Q1 | $8.32K | Hold |
300
| – | – | ﹤0.01% | 130 |
|
|
2023
Q4 | $8.64K | Hold |
300
| – | – | ﹤0.01% | 119 |
|
|
2023
Q3 | $9.95K | Hold |
300
| – | – | ﹤0.01% | 90 |
|
|
2023
Q2 | $11K | Hold |
300
| – | – | ﹤0.01% | 89 |
|
|
2023
Q1 | $12.2K | Sell |
300
-325
| -52% | -$14K | ﹤0.01% | 75 |
|
|
2022
Q4 | $32K | Hold |
625
| – | – | 0.01% | 54 |
|
|
2022
Q3 | $27K | Hold |
625
| – | – | 0.06% | 49 |
|
|
2022
Q2 | $33K | Hold |
625
| – | – | 0.07% | 45 |
|
|
2022
Q1 | $32K | Buy |
625
+325
| +108% | +$16.9K | 0.02% | 62 |
|
|
2021
Q4 | $18K | Hold |
300
| – | – | 0.01% | 89 |
|
|
2021
Q3 | $13K | Hold |
300
| – | – | 0.02% | 90 |
|
|
2021
Q2 | $12K | Hold |
300
| – | – | 0.01% | 99 |
|
|
2021
Q1 | $11K | Hold |
300
| – | – | ﹤0.01% | 118 |
|
|
2020
Q4 | $11K | Buy |
+300
| New | +$11K | ﹤0.01% | 70 |
|
|
2020
Q1 | – | Sell |
-280
| Closed | -$10K | – | 109 |
|
|
2019
Q4 | $10K | Hold |
280
| – | – | 0.01% | 86 |
|
|
2019
Q3 | $10K | Hold |
280
| – | – | 0.01% | 88 |
|
|
2019
Q2 | $12K | Hold |
280
| – | – | 0.01% | 81 |
|
|
2019
Q1 | $11K | Hold |
280
| – | – | 0.01% | 79 |
|
|
2018
Q4 | $12K | Hold |
280
| – | – | 0.01% | 63 |
|
|
2018
Q3 | $12K | Hold |
280
| – | – | 0.01% | 83 |
|
|
2018
Q2 | $10K | Hold |
280
| – | – | 0.01% | 93 |
|
|
2018
Q1 | $9K | Hold |
280
| – | – | 0.04% | 63 |
|
|
2017
Q4 | $10K | Hold |
280
| – | – | 0.01% | 70 |
|
|
2017
Q3 | $10K | Hold |
280
| – | – | 0.01% | 66 |
|
|
2017
Q2 | $9K | Buy |
280
+132
| +89% | +$4.16K | 0.01% | 64 |
|
|
2017
Q1 | $5K | Buy |
+148
| New | +$4.67K | ﹤0.01% | 74 |
|
|
2016
Q4 | – | Sell |
-7,536
| Closed | -$242K | – | 79 |
|
|
2016
Q3 | $242K | Buy |
7,536
+1,813
| +32% | +$60.6K | 0.2% | 18 |
|
|
2016
Q2 | $193K | Buy |
5,723
+2,240
| +64% | +$71.5K | 0.16% | 18 |
|
|
2016
Q1 | $105K | Buy |
3,483
+573
| +20% | +$16.4K | 0.1% | 24 |
|
|
2015
Q4 | $89K | Buy |
+2,910
| New | +$91.5K | 0.08% | 24 |
|
Other funds holding PFE
Stuart Chaussee & Associates's PFE Position: Q4 2025 in Review
Stuart Chaussee & Associates sold out of Pfizer (PFE) in Q4 2025, closing a stake of 300 shares — an estimated $7.64K sold.
Stuart Chaussee & Associates first reported a position in PFE in Q4 2015 and held it in 36 quarters. The position peaked at $242K in Q3 2016. 2,914 funds tracked by Wall St. Rank hold PFE as of Q4 2025.
- Stuart Chaussee & Associates reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
- Stuart Chaussee & Associates sold 300 Pfizer shares in Q4 2025, an estimated $7.64K.
- Stuart Chaussee & Associates first reported a position in Pfizer in Q4 2015 and held it in 36 quarters.
- Stuart Chaussee & Associates's Pfizer position peaked at $242K in Q3 2016.
- 2,914 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.
Based on Stuart Chaussee & Associates's 13F filing for Q4 2025.